Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $18.8200 (4.04%) ($17.9100 - $19.3200) on Thu. Jun. 18, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.37% (three month average) | RSI | 50 | Latest Price | $18.8200(4.04%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 2.3% a day on average for past five trading days. | Weekly Trend | TGTX declines -0.2% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(64%) ARKG(59%) ARKK(56%) IBB(55%) IWO(55%) | Factors Impacting TGTX price | TGTX will decline at least -3.685% in a week (0% probabilities). VIXM(-34%) VXX(-32%) UUP(-18%) DRIV(-3%) XLC(-1%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.685% (StdDev 7.37%) | Hourly BBV | 0 () | Intraday Trend | 4.6% | | | |
|
5 Day Moving Average | $18.1(3.98%) | 10 Day Moving Average | $17.95(4.85%) | 20 Day Moving Average | $18.65(0.91%) | To recent high | -13.8% | To recent low | 163.6% | Market Cap | $2.384b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |